Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (LUMINA 2)

NCT05002777 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05002777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05002777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (LUMINA 2)
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 7, 2021
Completion date
December 31, 2029
Enrollment
22 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

warm autoimmune hemolytic anemia (waiha)